FilingSEC EDGAR8-K
EyePoint Pharmaceuticals Updates DURAVYU Phase 3 LUGANO Results and Future Milestones
· SEC accepted
StagePhase 3
Filing content
The company updated results from the Phase 3 LUGANO trial for DURAVYU and outlined future development milestones, targeting an FDA NDA filing in the first half of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…